Skip to content

The assessment of pilomotor function using QPART (quantitative pilomotor axon-reflex test) in patients with diabetic neuropathy and patients with Parkinson's disease

The assessment of pilomotor function using QPART (quantitative pilomotor axon-reflex test) in patients with diabetic neuropathy and patients with Parkinson's disease - QPART 001

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00005033
Enrollment
72
Registered
2013-06-19
Start date
2013-08-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects G20 G63.2

Interventions

Group 1: In study arm 1, 24 patients with diabetic neuropathy will undergo the QPART method on both volar forearms. (Siepmann et al. Archives of Neurology 2012). Comparative standard autonomic measure

Sponsors

Institut für Klinische Pharmakologie Medizinische Fakultät Carl Gustav Carus Technische Universität Dresden
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Male and female patiens with diabetic neuropathy ages 18-75 years will be inculded following full written informed consent. Furthermore male and female healthy control subjects as wella as male and female patiens with Parkinson's disease ages 18-75 years will be inculded following full written informed consent. Each diagnosis (Parkinsion's disease or diabetic neuropathy) has to be cproven previously.

Exclusion criteria

Exclusion criteria: Patient arms: - intake of beta-blockers within 14 days previous to beginning of the study - intake of antidepressants within 3 months previous to beginning of the study - dermatologic comorbidities affecting the testing sites - known allergy to phenylephrine - consumption of more than 10 cigarettes per day - consumption of one alcoholic beverage per day - consumption of any nicotine, caffeine or alcohol at the testing day Control arm: -any acute of chronic disease -chronic intake of medication - consumption of more than 10 cigarettes per day - consumption of one alcoholic beverage per day - consumption of any nicotine, caffeine or alcohol at the testing day

Design outcomes

Primary

MeasureTime frame
Number of hair follicle silicone indentations - analysis through counting of the indentation in silicon scans- analysis on the day of measurement

Secondary

MeasureTime frame
Volume and area spread of hair follicle silicone indentations - analysis through digital image analysis of the indentations in silicon scans- analysis on the day of measurement

Countries

Germany

Contacts

Public ContactTimo Siepmann

Klinik und Poliklinik für Neurologie Universitätsklinikum Carl Gustav Carus

timo.siepmann@uniklinikum-dresden.de+49 (0)351 458 3565

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026